EUVIMEDEUVIMED entdecken
Crossref

Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro

Lili Zhang, Yanxia Sun, Zhen Yang, Ping Xia

Transplant Immunology · 2023

DOI: 10.1016/j.trim.2023.101949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2023. Verfasst von Lili Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, …. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Toll-Like Receptor 4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation for Innovative Research Groups of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asarinin has been found to prolong allograft survival and inhibit post-transplant immune rejection via the Toll-like receptor (TLR) signaling pathway. However, the underlying mechanism is not completely understood. Therefore, elucidating the possible pathophysiological role of asarinin in the TLR signaling pathway is essential. Here, dendritic cells were isolated from Sprague-Dawley® rats and cultured with splenocytes from Wistar rats treated with asarinin, lipopolysaccharide (LPS), and/or dimethyl sulfoxide. mRNA expression of TLR-2, TLR-4, myeloid differentiation factor 88 (MyD88), and nuclear factor kB (NF-kB) was determined using real-time polymerase chain reaction. Interleukin (IL)-6 and IL-12 levels were examined using an enzyme-linked immunosorbent assay. LPS resulted in an increase in the expression of TLR-2 rather than TLR-4 and MyD88. Furthermore, it inhibited the secretion of IL-6 and IL-12. MyD88 can be silenced after lentiviral transduction, and LPS can activate MyD88, whereas asarinin can inhibit this kind of activation. The effect of LPS and asarinin on TLR-4 could only be achieved when MyD88 was not silenced by lentivirus transduction. Therefore, asarinin might suppress TLR-4-mediated activation via the MyD88-dependent pathway. Overall, asarinin has a pre-application effect in inhibiting graft rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Differentiation Factor 88Toll-Like Receptor 4RatsAnimalsToll-Like Receptor 2Rats, Sprague-DawleyRats, WistarLipopolysaccharidesSignal TransductionInterleukin-12NF-kappa BDioxolesLignans

Stichwörter der Autor:innen

AsarininDendritic cellMyeloid differentiation factor 88Nuclear factor kBToll-like receptor

Substanzen

Myeloid Differentiation Factor 88Toll-Like Receptor 4Toll-Like Receptor 2LipopolysaccharidesInterleukin-12NF-kappa BsesaminDioxolesLignans

Autor:innen und Institutionen

  • Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, PR China.
  • Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, PR China. Electronic address: drsunyanxia@126.com.

Förderung

  • National Natural Science Foundation of China
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Zitieren

APA

Zhang, L., Sun, Y., Yang, Z., & Xia, P. (2023). Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101949

Vancouver

Zhang L, Sun Y, Yang Z, Xia P. Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro. Transplant Immunology. 2023. doi:10.1016/j.trim.2023.101949

BibTeX
@article{Zhang2023,
  author = {Zhang, Lili and Sun, Yanxia and Yang, Zhen and Xia, Ping},
  title = {Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro},
  journal = {Transplant Immunology},
  year = {2023},
  doi = {10.1016/j.trim.2023.101949}
}
Kostenlos starten →